Review on experimental study of CpG DNA treatment in murine allergy model

Authors

  • Г.Ням-Очир АШҮУИС, Сувилахуйн сургууль, Анагаахын суурь шинжлэх ухааны тэнхим Author
  • Ч.Гансүх АШҮУИС, Био-Анагаахын сургууль, Дархлаа судлалын тэнхим Author
  • Б.Өлзийсайхан АШҮУИС, Био-Анагаахын сургууль, Дархлаа судлалын тэнхим Author
  • Г.Цолмонцэцэг Баянгол дүүргийн Эрүүл мэндийн төв, Хүүхдийн эмнэлэг Author
  • Л.Энхсайхан Монгол улсын Засгийн газар, Эрүүл мэндийн яам Author

Keywords:

Allergic rhinitis, CpG-ODNs (Oligodeoxynucleotides), bronchial asthma

Abstract

Allergic diseases are on the rise in the world's population and occur in many types, including bronchial asthma, allergic rhinitis, conjunctivitis, and dermatitis. In allergic diseases, the Th1-type immune response is suppressed and the Th2-type response is activated. The use of CpG (Cytosine phosphate Guanine) DNA in the treatment of allergic diseases activates the Th1-type immune response, suppresses the Th2-type immune response, and reduces the production of IgE from B cells. CpG DNA is a short molecule that contains the unmethylated cytosine and guanine dinucleotides in DNA. To determine the main effects of CpG DNA therapy in allergic rhinitis and bronchial asthma, research articles and analysis have shown that CpG DNA therapy is important in the treatment of allergic diseases.

In the MNUMS Digital Library

View this article in the digital library →

Author research profiles: Г.Ням-Очир, Ч.Гансүх, Л.Энхсайхан

Боть 17, №6 (62) 2021

Downloads

Published

2021-09-01

Issue

Vol. 17 No. 6 (2021)

Section

Review Articles

License

Articles in this journal are published under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Anyone may copy, distribute and adapt the work, provided the authors and the source are properly credited. Copyright remains with the authors.